Second Sight Medical Products

Equities

EYES

US81362J3086

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.62 ^USD	-0.61%		-10.00%	-28.95%

2022	Vivani Medical Starts Nasdaq Trading Lower	MT
2022	Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index	CI

Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 13, 2021 at 04:11 pm EDT

Second Sight Medical Products, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 2.296 million compared to USD 3.116 million a year ago. Net loss was USD 2.294 million compared to USD 3.100 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.15 a year ago. For the half year, operating loss was USD 5.139 million compared to USD 12.020 million a year ago. Net loss was USD 5.137 million compared to USD 11.986 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.67 a year ago.

Latest news about Second Sight Medical Products

Vivani Medical Starts Nasdaq Trading Lower	22-08-31	MT
Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index	22-08-31	CI
Second Sight Medical Completes Merger With Nano Precision Medical; Changes Name to Vivani Medical	22-08-30	MT
Nano Precision Medical, Inc. completed the acquisition of Second Sight Medical Products, Inc. in a reverse merger transaction.	22-08-29	CI
Second Sight Medical Products Starts Trading on Split-Adjusted Basis; Shares Down	22-08-19	MT
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Second Sight Medical Products, Inc. Announces Resignation of Edward Randolph as its Chief Operating Officer, Effective August 19, 2022	22-08-05	CI
Second Sight Medical Products, Inc. has Changed its Name to Vivani Medical, Inc	22-07-27	CI
Second Sight Medical Products Receives $1.1 Million of Funding for Visual Cortical Prosthesis Trial	22-07-18	MT
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study	22-07-18	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
North American Morning Briefing : Dow Futures -2-	22-03-25	DJ
North American Morning Briefing : Stock Futures -3-	22-03-18	DJ
Transcript : Nano Precision Medical, Inc., Second Sight Medical Products, Inc. - M&A Call	22-02-08
Second Sight Medical Products to Acquire Nano Precision Medical in All-Stock Deal	22-02-08	MT
Nano Precision Medical, Inc. entered into term sheet to acquire Second Sight Medical Products, Inc. for approximately $180 million in a reverse merger transaction.	22-02-06	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Second Sight Medical Products, Inc.(NasdaqCM:EYES) added to S&P Global BMI Index	21-09-20	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Second Sight Medical Products : Obtains New NIH Grant Supplement for Visual Neuroprostheses Study	21-08-11	MT
Second Sight Medical Products, Inc. Receives Grant from the National Institutes of Health	21-08-04	CI
North American Morning Briefing : Stock Futures -3-	21-07-23	DJ
Certain Common Stock of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	21-07-22	CI
Certain Stock Options of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	21-07-22	CI
Certain Warrants of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	21-07-22	CI

Chart Second Sight Medical Products

Duration

Period

More charts

Company Profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.

Sector

More about the company